GE Healthcare, MDS Pharma Hope New Genotoxicity Assay Protocol Will Spur IN Cell, Tox Assay Sales | GenomeWeb

GE Healthcare and MDS Pharma Services this week announced the availability of a new micronucleus assay protocol for GE Healthcare's IN Cell 1000 and 3000 high-content screening platforms that is expected to more accurately predict genotoxicity in early-stage drug discovery.

The assay will be available as part of MDS Pharma's contract pharmaceutical research offerings and is a key component of its growing portfolio of early-stage, cell-based assays for assessing the potential toxicity of drug candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.